AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03757676 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Oriented Play
Description: Participants in this group were asked to download and play Pokémon Go and achieve a minimum player level of 20 within the game during the study period. They were given materials that described game features and functions to show them how to play the game. There were no restrictions on which features to pursue within the game to achieve this goal nor on how long or how frequent their play sessions should be. Upon reaching their goal (Level 20), participants were encouraged to continue to play as much or as little as they desired. Participants were asked to wear the Fitbit device and use the GPS app on their mobile phones during the 6-week study period. Starting the fifth week, participants were prompted to complete five (5) brief daily surveys on their phones via the EMA app.
Study NCT00812097 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Mentor Siltex® Contour Profile Gel Mammary Prosthesis
Description: The MENTOR® MemoryShape™ Breast Implant is a silicone elastomer mammary device with a textured surface.
Study NCT03744234 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRP
Description: Autologous platelet-rich plasma
Study NCT03744234 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Steroid Injection
Description: Steroid injection
Study NCT02039388 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lavage of the Cavum uteri and proximal Fallopian tubes, performed in the luteal phase of the female cycle
Study NCT02035943 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Insulin separated
Description: separate continuos infusion of insulin
Study NCT02035943 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Insulin added to parenteral nutrition
Description: Insulin added to parenteral nutrition
Study NCT00652587 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hepatectomy and transcatheter arterial chemoembolization
Description: partial hepatectomy with adjuvant transcatheter arterial chemoembolization
Study NCT00652587 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hepatectomy
Description: hepatectomy alone
Study NCT01585649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipegfilgrastim
Description: Lipegfilgrastim 100ug/kg
Study NCT02299934 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Magnetic Resonance Imaging (MRI)
Description: MRI sequences for visualisation of the blood supply of liver without contrast agent.
Study NCT02299934 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Compurtized Tomgraphy (CT)
Description: CT including CT Angiography (CTA) for the evaluation of hepatic vasculature.
Study NCT04036760 — intervention group
Intervention type: BEHAVIORAL
Intervention: Research transitional care coordination
Description: Though care coordination was offered to all HCV positive inmates who are approached,the care coordination will still constitute a research intervention that requires informed consent, rather than a new uniform standard of care, to allow maximum autonomy for this incarcerated population.
Study NCT00716521 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: single oral dose placebo
Study NCT00716521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolpidem
Description: single oral dose, 5 mg zolpidem
Study NCT00716521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolpidem
Description: single oral dose, 10 mg zolpidem
Study NCT03590561 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High caloric diet
Description: After dietary counseling, subjects will receive high caloric snacks for five days.
Study NCT00989326 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Monitoring
Description: Both patient groups are followed for 18 months and will be followed with Home Monitoring switched on. The data from the CONTROL group will not be presented online to the attending physician, but a retrospective analysis on differences between the two groups will be performed.
Study NCT00989326 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Monitoring
Description: Both patient groups are followed for 18 months and will be followed with Home Monitoring switched on. The data from the CONTROL group will not be presented online to the attending physician, but a retrospective analysis on differences between the two groups will be performed.
Study NCT02984475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study NCT03778333 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cells
Description: IV therapy with autologous bone-marrow derived mesenchymal stem cells
Study NCT01655407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Engineered Skin Substitute
Description: The total burn wound area covered will range from 288 cm\^2 to 5,600 cm\^2 (based on availability of matched-pair burn sites of similar area and depth) and this total grafting area will be divided equally for treatment with ESS-W and AG.~ESS-W will be applied to the appropriate recipient site, according to the randomization schedule, by the surgeon using two pairs of forceps. Sufficient ESS-W sheets will be used to cover the recipient site. The ESS-W grafts will be stapled in place.
Study NCT01655407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous Engineered Skin Substitute
Description: The total burn wound area covered will range from 288 cm\^2 to 5,600 cm\^2 (based on availability of matched-pair burn sites of similar area and depth) and this total grafting area will be divided equally for treatment with ESS-W and AG.~ESS-W will be applied to the appropriate recipient site, according to the randomization schedule, by the surgeon using two pairs of forceps. Sufficient ESS-W sheets will be used to cover the recipient site. The ESS-W grafts will be stapled in place.
Study NCT01655407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Split-Thickness Autograft (AG)
Description: The total burn wound area covered will range from 288 cm\^2 to 5,600 cm\^2 (based on availability of matched-pair burn sites of similar area and depth) and this total grafting area will be divided equally for treatment with ESS-W and AG.~The AG regimen occurs in stages, beginning with excision of the burned skin, followed by temporary wound coverage (e.g. cadaveric skin allografts, porcine xenograft, synthetic or biologic dressings or medical devices) to achieve wound homeostasis, and completed by permanent wound closure using autologous skin.
Study NCT01655407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Split-Thickness Autograft (AG)
Description: The total burn wound area covered will range from 288 cm\^2 to 5,600 cm\^2 (based on availability of matched-pair burn sites of similar area and depth) and this total grafting area will be divided equally for treatment with ESS-W and AG.~The AG regimen occurs in stages, beginning with excision of the burned skin, followed by temporary wound coverage (e.g. cadaveric skin allografts, porcine xenograft, synthetic or biologic dressings or medical devices) to achieve wound homeostasis, and completed by permanent wound closure using autologous skin.
Study NCT04353947 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Mini Cognitive Examination (MCE)
Description: This test provides information on temporal and spatial orientation, fixation, concentration and calculation, memory and language and construction.
Study NCT04353947 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Beck Depression Inventory-II (BDI-II)
Description: This test evaluates the absence or presence of depressive symptoms.
Study NCT04353947 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Global Deterioration Scale (GDS)
Description: This scale measures the level of deterioration of the subject.
Study NCT03341429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide Pen Injector [Saxenda]
Description: Daily injection of GLP-1 agonist (liraglutide 3.0 mg) for obese patients presenting poor weight loss (\<20%) after bariatric surgery and suboptimal GLP-1 levels.
Study NCT03341429 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily subcutaneous injection
Study NCT01773902 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Dose Protein (Individualized)
Description: Protein supplementation according to breast milk content aiming for 4.5g/kg/d of enteral protein if \<1500g b.w. or 4.0g/kg/d of enteral protein if >1500g b.w. until 1 week before discharge
Study NCT01773902 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Dose Protein (Standardized)
Description: Protein supplementation independent of individual breast milk content using a new high-dose-protein breast milk fortifier until 1 week before discharge
Study NCT01773902 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard Protein Supplementation
Description: Protein supplementation independent of individual breast milk content using a standard-dose-protein breast milk fortifier until 1 week before discharge
Study NCT03228576 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Extended release Tacrolimus-Everolimus association
Description: Envarsus® will be used as Tacrolimus Certican® will be used as Everolimus
Study NCT01993368 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: flow cytometry
Description: These populations will be identified by different combinations of antibodies to identify:~* T cell subsets (CD45, CD3, CD4, CD8, CD45RA, CD69, CD28, TCRαβ, TCRγδ, CD197, CD25, FoxP3), B cells (CD45, CD19, HLA-DR, IgA), cells NK (CD45, CD3, CD56).~* Monocyte subsets (CD45, CD11b, CD14, CD16, CD1c, HLA-DR)~* Mesenchymal stromal cells (CD45, HLA-ABC, CD105, CD90, CD73)
Study NCT03324009 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 2-stage screen
Description: Pap smear is currently the standard of care for cervical cancer screening in Botswana. In this study, participants will undergo HPV DNA testing at the time of Pap smear collection. If HPV DNA test is positive, they will be referred for colposcopy. Patients who have an HPV negative test but positive Pap smear will be referred for colposcopy per Botswana cervical cancer screening guidelines.
Study NCT04069520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aNMT Biofeedback
Description: aNMT biofeedback is created by calculating kinematic and kinetic data in real-time from the athlete's own movements. These values determine real-time transformations of the stimulus shape the athlete views via augmented-reality (AR) glasses during movement performance. The athlete's task is to move so as to create (animate) a particular stimulus shape that corresponds to desired values of the biomechanical parameters targeted by the intervention. The aNMT biofeedback occurs during neuromuscular training sessions. The neuromuscular training is a 18 session, pre-season training program occurring over 6 weeks.
Study NCT04069520 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Biofeedback
Description: Sham biofeedback provides a similar phenomenological experience to aNMT biofeedback for athletes-both groups experience a shape that changes with their movements-but the sham biofeedback will not provide usable information to modify movement parameters during critical movement phases. The sham biofeedback occurs during neuromuscular training sessions. The neuromuscular training is a 18 session, pre-season training program occurring over 6 weeks.
Study NCT01068912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: 1000 mg favipiravir BID x 1 day, and 400 mg favipiravir BID x 4 days
Study NCT01068912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: High-dose favipiravir regimen: 1200 mg favipiravir BID x 1 day, and 800 mg favipiravir BID x 4 days
Study NCT01068912 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Placebo BID x 1 day, and Placebo BID x 4 days
Study NCT03634150 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nerofe is a first in class derivative of a human hormon-peptide(TCApF), with Cancer suppressive properties.
Description: Once weekly treatment, with IV doses of Nerofe (96mg\\m2) and low dose (20 mg/m2) Doxorubicin 5 or 24 hours from one another) .
Study NCT01784536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single-Dose IV Oritavancin Diphosphate
Description: Oritavancin will be administered as a single IV infusion. The infusion will last approximately 3 hours.
Study NCT00309244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere® Insulin Inhalation Powder
Description: Inhalation, 15U/30U
Study NCT00309244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)
Description: BPR 70/30, which is a premix of intermediate acting and rapid acting insulin given sc
Study NCT03211832 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dissemination of public health knowledge
Description: Participating local health departments will help develop and choose dissemination strategies they prefer for their staff working in and supporting diabetes and chronic disease prevention and control to receive. Dissemination strategies may include multi-day in-person training workshops, electronic information exchange modalities, remote technical assistance, and information on ways to enhance organizational climates favorable to evidence-based diabetes prevention and control.
Study NCT00857051 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hotline Service
Description: A 24 hour hotline to answer questions about baby care or mother self-care. Hotline will be answered by a midwife and answers will be based on algorithms.
Study NCT00857051 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Film
Description: A DVD addressing common stressors in the early postpartum.
Study NCT04353947 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Memory alteration test (M@T)
Description: In this test different memory subtypes are evaluated.
Study NCT04039750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antibiotic rinse with suction
Description: antibiotic rinse with suction
Study NCT04039750 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: suction only
Description: no irrigation, suction only
Study NCT02179658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPT-80
Description: oral
Study NCT02179658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vancomycin
Description: oral
Study NCT04353947 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Spanish-Complutense Verbal Learning Test (TAVEC)
Description: This test is used to assess immediate memory, deferred memory and learning ability.
Study NCT04353947 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Barcelona test (BT)
Description: This test evaluates categorical evocation and verbal fluency. The categorical recall subtest consists of recalling the maximum number of words linked to a specific category animals in 1 minute. In the case of verbal fluency, the subject is asked to evoke the maximum number of words that begin with the letter p in 3 minutes.
Study NCT04353947 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Rey-Osterrieth Complex Figure Test (ROCFT)
Description: In this test, the person must carefully copy a complex geometric drawing, which must be memorized later. The first part evaluates multiple cognitive processes such as planning, motor skills, working memory, and visual-constructive and spatial skills. In the second part, memory is evaluated.
Study NCT04353947 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Frontal assessment battery (FAB)
Description: This test is a composite tool for assessing executive functions related to the frontal lobe.
Study NCT04353947 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Positive and Negative Affect Scale (PANAS)
Description: It is a self-report questionnaire made up of 20 items (10 of positive affect and another 10 of negative affect) that the subject must answer, obtaining in this way a score in positive affectivity (AP subscale) and another in negative affectivity (AN subscale).
Study NCT04353947 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Auto-Assessment Manikins (SAM)
Description: It is a self-report questionnaire that assesses the emotional response of the subject, in this case, through a mood induction task that plays different films scenes.
Study NCT00656812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 on day 1 of a 21-day treatment cycle
Study NCT00656812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-CdA
Description: 0.1 mg/kg s.c. on days 1 - 4 of a 21-day treatment cycle
Study NCT04359615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: This will be drug only used in the intervention arm of our study, designed mainly to assess the additional efficacy and safety of Favipiravir in COVID-19 patients.
Study NCT04359615 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: This Drug will be used in all arms as mandated by our governmental guidelines.
Study NCT04359615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: This Drug will be used in all arms as mandated by our governmental guidelines.
Study NCT02455011 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: REMD-477
Study NCT02455011 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REMD-477
Study NCT02464358 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMB Intervention Group
Description: Participants in the IMB group received information specific to HPV, cervical cancer, and the HPV vaccine. This information was delivered in a group setting, and it was delivered via a PowerPoint presentation that included short video clips.
Study NCT02464358 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Participants in the attention control arm watched a PowerPoint that contained a series of short video clips encompassing aspects of women's general and sexual health. This was also conducted in a group setting.
Study NCT02846428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: 5-FU will be administered at 500 mg/m\^2 by short IV infusion on Day 1 of each 21-day cycle during neoadjuvant treatment period for 4 cycles.
Study NCT02846428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will be administered at 900 mg/m\^2 orally twice daily on Days 1-14 of each 21-day cycle for 4 cycles during neoadjuvant treatment period.
Study NCT02846428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered at 500 mg/m\^2 by short IV infusion on Day 1 of each 21-day cycle for 4 cycles during neoadjuvant treatment period.
Study NCT02846428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered at 500 mg/m\^2 by short IV infusion on Day 1 of each 21-day cycle for 4 cycles during neoadjuvant treatment period.
Study NCT02846428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel will be administered at 100 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles during adjuvant treatment period.
Study NCT02846428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered at 100 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles during adjuvant treatment period.
Study NCT02846428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: Epirubicin will be administered at 100 mg/m\^2 by short IV infusion on Day 1 of each 21-day cycle for 4 cycles during neoadjuvant treatment period.
Study NCT02846428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin will be administered at 100 mg/m\^2 by short IV infusion on Day 1 of each 21-day cycle for 4 cycles during neoadjuvant treatment period.
Study NCT04331405 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Allogeneic Umbilical Cord Blood Mononuclear Cells (hUCBMCs) systemic (i.v.) infusions
Description: HUCBMCs samples were prepared for infusion in the specialized laboratory of Cord Blood Bank (CryoCenter Ltd) and transported to the clinic immediately within 2 hours in the Dry Shipper. All samples were chosen according to patients blood group and rhesus-factor.~All samples were examined for hemotransmissive infections and cell viability prior to the preparation.~Obtained samples were infused through the blood transfusion systems with additional filter after 3 tests for biological and individual compatibility and tolerance.~Each patient of the pilot group received 4 cell infusions (1 infusion per week) with 1 week interval during the in-hospital treatment.
Study NCT02370862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neostigmine and Glycopyrrolate
Study NCT01501097 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Continuous Renal Replacement Therapy
Description: Patients will be randomized to either arm :early HV-crrt(50ml/kg/h) or Control group
Study NCT04255134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept Injection
Description: Subjects will be randomized to treatment with either abatacept or adalimumab
Study NCT04255134 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab Injection
Description: Subjects will be randomized to treatment with either abatacept or adalimumab